X4 Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.